Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.51 USD

73.51
8,106,663

+0.21 (0.29%)

Updated Jul 18, 2024 04:00 PM ET

After-Market: $73.37 -0.14 (-0.19%) 6:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $77.73, moving -0.61% from the previous trading session.

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis

Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

These leveraged ETFs won last week despite a broader market bloodbath.

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection

Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.

Benjamin Rains headshot

Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) shares have surged 30% in 2020 as investors clamor for stocks that appear immune to the coronavirus economic downturn...

Neena Mishra headshot

Can Buffett-Style Investing Succeed Today? Stocks & ETFs to Consider

Companies with strong competitive advantage are expected to succeed in this challenging environment.

Mark Vickery headshot

No Foolin': ADP Report Better than Expected

The ADP headline number came out much better than expected at -27K private sector payroll totals; expectations were for -125K.

ADP Report Better than Expected

ADP Report Better than Expected

Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $74.76, marking a -1.54% move from the previous day.

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

Gilead Expands Access to Experimental Coronavirus Treatment

Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.

Sejuti Banerjea headshot

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

The WHO's Solidarity testing project could be good news for the world.

Sanofi Begins Kevzara Study for Severe Coronavirus Infection

Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences

Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir

Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals

Daniel Laboe headshot

How To Play The W-Shaped Recovery

Patience is the name of the game during market downturns

Daniel Laboe headshot

Top 5 Drug Stocks To Stop The Coronavirus Pandemic

It is only a matter of time before this virus anxiety is a thing of the past.

Coronavirus Drug Development Race to Boost These 4 Stocks

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.